References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailType II collagen peptides for measuring cartilage degradation
Henrotin, Yves ULg; Deberg, Michelle ULg; Dubuc, J. E. et al

in Biorheology (2004), 41(3-4), 543-547

This paper describes two new immunoassays for a peptide of the triple helix of type II collagen (Coll 2-1) and its nitrated form (Coll 2-1 NO2). In healthy subjects aged between 20 and 65 years old, Coll ... [more ▼]

This paper describes two new immunoassays for a peptide of the triple helix of type II collagen (Coll 2-1) and its nitrated form (Coll 2-1 NO2). In healthy subjects aged between 20 and 65 years old, Coll 2-1 and Coll 2-1 NO2 levels in serum were in means 125.13+/-3.71 and 0.16+/-0.08 nmol/l, respectively. These levels did not significantly vary with age. However, up to 45 years of age, Coll 2-1 NO2 levels in women were significantly higher than in men. In patients with knee osteoarthritis (OA), Coll 2-1 in serum was found to be elevated compared to healthy controls (267.45+/-26.42 nmol/l vs 126.78+/-6.61 nmol/l). Further, we have demonstrated that an increase of the urinary levels of Coll 2-1 or Coll 2-1 NO2 over 1 year was predictive of joint space narrowing progression in OA patients. In conclusion, these preliminary results indicate that Coll 2-1 could be a predictive marker of knee OA progression. [less ▲]

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailTraitement de l’ostéoporose postménopausique en 2004.
Reginster, Jean-Yves ULg; Devogelaer, JP

in L'agenda Gynécologique (2004), 36

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailFractures vertébrales ostéoporotiques et raloxifène (Evista°).
Reginster, Jean-Yves ULg

in Patient Care (2004), 27

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailEvaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a cost-effective strategy for osteoporosis screening?
Ben Sedrine, Wafa ULg; Ethgen, Olivier ULg; Devogelaer, Jean-Pierre et al

in Aging Clinical & Experimental Research (2004), 16(5), 413-419

BACKGROUND AND AIMS: The Belgian Social Security Institute (hereafter INAMI) proposes a list of conditions to be considered as a prerequisite for reimbursement of Bone Mineral Density (BMD) measurements ... [more ▼]

BACKGROUND AND AIMS: The Belgian Social Security Institute (hereafter INAMI) proposes a list of conditions to be considered as a prerequisite for reimbursement of Bone Mineral Density (BMD) measurements. The aim of this paper was to evaluate the diagnostic accuracy of the proposed criteria for identifying osteoporosis, and to gauge how useful they are for more rational application of densitometry tests. METHODS: 3748 Caucasian women aged at least 50 years old were recruited consecutively from an outpatient university center, from the database of which all relevant data corresponding to the INAMI list of clinical factors, as well as patients' age, weight and height, were collected. BMD measurements using dual X-ray absorptiometry were reported at the spine and hip regions. Diagnostic accuracy was evaluated through measures of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Additionally, from ROC analysis, benchmark values for age and body mass index were identified and then, used alone and in combination with the INAMI test, were applied to define various screening strategies. For each of them, associated costs per osteoporotic patient detected were estimated. Cost estimates refer only to the costs associated with the densitometric procedure from the perspective of the reimbursement health authorities. RESULTS: Applying INAMI criteria for detecting osteoporosis at any of the considered sites yielded sensitivity of 68.9%, specificity of 50.7%, PPV of 42.9% and NPV of 57.3%. Comparison of incremental costs per patient of the different strategies revealed that, with 67.1 Euros, the option of opening BMD coverage to women on the basis of the INAMI conditions would be more cost-effective than mass screening (90.1 Euros) or applying the age criterion alone (70.2 Euros). However, the BMI condition seems to act as a better indicator of risk than the INAMI criteria in those meeting the age condition (35.4 Euros). CONCLUSIONS: The accuracy of the INAMI proposal turns out to be quite unsatisfactory, and did not adequately cover the population at risk of osteoporosis. From a resource allocation perspective, the best strategy by far would be to recommend using concomitantly INAMI, age and BMI-selective criteria. Some adaptations could enhance the usefulness of the INAMI proposals as a selective approach for BMD referral and reimbursement. [less ▲]

Detailed reference viewed: 58 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia
Sawicki, A; Reginster, Jean-Yves ULg; Roux, C et al

in Osteoporosis International (2004), 15(S1), 119-120

Detailed reference viewed: 8 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with post-menopausal osteoporosis.
Adami, S; Meunier, J; Devogelaer, JP et al

in Calcified Tissue International (2004), 74(S1), 37-38

Detailed reference viewed: 18 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: a new paradigm in the treatment of osteoporosis.
REGINSTER, Jean-Yves ULg; LECART, Marie-Paule ULg; DEROISY, Rita ULg et al

in Expert Opinion on Investigational Drugs (2004), 13(7), 857-64

In vitro, strontium ranelate increases collagen and non-collagenic protein synthesis by mature osteoblast-enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug ... [more ▼]

In vitro, strontium ranelate increases collagen and non-collagenic protein synthesis by mature osteoblast-enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated osteoclast, a preincubation of bone slices with strontium ranelate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. The drug was administered in 160 early postmenopausal women, in a 24-month, double-blind, placebo-controlled, prospective randomised study. At the conclusion of the study, the percentage variation of lumbar bone mineral density (BMD) from baseline was significantly different in the group receiving strontium ranelate 1000 mg/day as compared with placebo (+5.53 versus -0.75%, respectively). Increase in total hip and neck BMD averages were 3.2 and 2.5%, respectively. The effect of strontium ranelate in postmenopausal women with established osteoporosis was assessed during a multinational, prospective, double-blind, randomised, placebo-controlled trial. Strontium ranelate (500, 1000, 2000 mg/day) or placebo were given to 353 Caucasian women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study, the annual increase in lumbar BMD of the group receiving strontium ranelate 2000 mg was 7.3% (p < 0.001). A significant increase in bone alkaline phophatase (p = 0.002) over a 6-month period and a significant decrease in N-telopeptide crosslinks (p = 0.004) throughout the 2-year period were seen in the group receiving 2000 mg of strontium ranelate. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. Bone histomorphometry showed no mineralisation defects. The primary analysis of the SOTI study, evaluating the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patients experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture in the group treated with strontium ranelate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture was also demonstrated in the patients treated for > or = 18 months. [less ▲]

Detailed reference viewed: 20 (6 ULg)
Full Text
Peer Reviewed
See detailLes nouveaux médicaments de l'arthrose
Reginster, Jean-Yves ULg; Henrotin, Yves ULg

in Pharma-Sphère (2004), 85

Detailed reference viewed: 14 (10 ULg)
Full Text
Peer Reviewed
See detailTraitement structurel de l'arthrose : le point en 2004
Reginster, Jean-Yves ULg; LECART, Marie-Paule ULg; SARLET, Nathalie ULg

in Ortho-Rhumato (2004), 2(3), 52-54

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailL'ostéodensitométrie
Devogelaer, Jean-Pierre; Reginster, Jean-Yves ULg

in Ortho-Rhumato (2004), 2

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailValidation of OSIRIS, a prescreening tool for the identification of women with an increased risk of osteoporosis.
REGINSTER, Jean-Yves ULg; Ben Sedrine, Wafa ULg; Viethel, P. et al

in Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology (2004), 18(1), 3-8

According to the recent recommendations of the European Community and the World Health Organization, identification of risk factors for fracture or low bone mineral density (BMD) should help health ... [more ▼]

According to the recent recommendations of the European Community and the World Health Organization, identification of risk factors for fracture or low bone mineral density (BMD) should help health professionals to make a better use of bone densitometry. This includes helping patients to modify their behaviour and act on modifiable risk factors (correction of low calcium intake and vitamin D deficiencies, etc.) and also to provide evidence-based guidance for starting a treatment when necessary. In this context, we previously developed a clinical scoring index, OSIRIS (OSteoporosis Index of RISk), for classifying women into three categories of risk of osteoporosis. In order to evaluate the discriminatory performance of OSIRIS, we performed the present prospective study in a sample of 889 postmenopausal women from France. The osteoporosis risk depends on the OSIRIS category. Thus, 62% of women in the 'high-risk' category (OSIRIS < or = -3) were osteoporotic, compared to 34% of women in the 'intermediate-risk' category (OSIRIS ranged between -3 and +1) and only 16.8% of women in the 'low-risk' category (score OSIRIS > 1). These results might contribute to the development of more efficient screening strategies for osteoporosis. The patients in the low-risk category do not require immediate BMD testing; women with 'intermediate risk' have to be carefully followed by their doctor with BMD testing decided on a case-by-case basis; for those within the high-risk category, treatment may be initiated immediately and BMD testing performed either to assess the efficacy of the treatment or to increase the long-term compliance of the patient. In conclusion, for clinical practice, a user-friendly tool has been developed. This tool, called OSIRIS, as far as a simple rule allows, identifies the level of osteoporosis risk in women. [less ▲]

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis prevalence in men varies by the normative reference
Richy, F.; Gourlay, M. L.; Garrett, J. et al

in Journal of Clinical Densitometry (2004), 7

Controversy surrounds which normative data should be used to estimate osteoporosis prevalence in men. Prevalence estimates may vary significantly when different normative standards are applied. Five ... [more ▼]

Controversy surrounds which normative data should be used to estimate osteoporosis prevalence in men. Prevalence estimates may vary significantly when different normative standards are applied. Five normative datasets (NHANES female norms, local female norms, Hologic densitometer manufacturer female norms, NHANES male norms, Hologic male norms) were used to estimate the prevalence of osteoporosis by World Health Organization diagnostic criteria in a study population of 311 consecutive men between the age of 30 and 91 (mean 60.3 yr) referred to an outpatient osteoporosis center between January 1996 and December 1998. Statistically significant variations were seen in osteoporosis prevalence measured at three anatomical sites. The greatest relative variation was seen for the total femur, where osteoporosis prevalence ranged from 7.0% (NHANES and Hologic female norms) to 15.6% (NHANES male norms). The least relative variation was seen at the lumbar spine, where prevalence ranged from 18.1% (Hologic female norms) to 29.6% (local female norms). When considering osteoporosis at any site, prevalence was lowest (23.5%) based on Hologic female norms and highest (35.8%) based on local female norms. Interpretation of prevalence data should include an assessment of how normative standards influence reporting of the population at high risk of fracture. [less ▲]

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailTreatment of osteoporosis with biphosphonates - Do compliance and persistence matter ?
Reginster, Jean-Yves ULg; LECART, Marie-Paule ULg

in Business briefing : Long-term Healthcare (2004), 5

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailFrom sample size to effect-size : small study effect investigation (SSEi)
Richy, F.; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Internet Journal of Epidemiology (2004), 1(2),

Detailed reference viewed: 49 (6 ULg)
Full Text
Peer Reviewed
See detailResponders to glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Pavelka, K.; Richy, F. et al

in Osteoporosis International (2004), 12(SB), 76

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailOnce-monthly oral ibandronate a new bisphosphonate dosing concept
Reginster, Jean-Yves ULg; Miller, P.; Delmas, P. et al

in Calcified Tissue International (2004), 74(S1), 85

Detailed reference viewed: 4 (2 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia
Sawicki, A.; Reginster, Jean-Yves ULg; Roux, C. et al

in Calcified Tissue International (2004), 74(S1), 84

Detailed reference viewed: 9 (2 ULg)